BPTH - Bio-Path Holdings, Inc.
| Previous Close | 1.71 |
| Open | 1.71 |
| Bid | 0.00 x 1100 |
| Ask | 0.00 x 1000 |
| Day's Range | 1.71 - 1.75 |
| 52 Week Range | 1.54 - 5.90 |
| Volume | 21,482 |
| Avg. Volume | 312,969 |
| Market Cap | 19.506M |
| Beta | 2.23 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.80 |
| Earnings Date | Aug 8, 2018 - Aug 13, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 15.00 |
- Simply Wall St.•7 days ago
With A -19.42% Earnings Drop, Is Bio-Path Holdings Inc’s (NASDAQ:BPTH) A Concern?
For long-term investors, assessing earnings trend over time and against industry benchmarks is more beneficial than examining a single earnings announcement at a point in time. Investors may find myRead More...
- Associated Press•7 days ago
Bio-Path: 1Q Earnings Snapshot
The Bellaire, Texas-based company said it had a loss of 17 cents per share. The company's shares closed at $1.76. A year ago, they were trading at $5.31. _____ This story was generated by Automated Insights ...
- GlobeNewswire•7 days ago
Bio-Path Holdings Reports First Quarter 2018 Financial Results
Bio-Path Holdings, Inc., (BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced its financial results for the first quarter ended March 31, 2018 and provided an update on recent corporate developments. “Throughout the first quarter of 2018, we made major strides advancing our RNAi nanoparticle drugs for the treatment of a variety of cancers with limited treatment options. Specifically, we were delighted to publish and present data in support of our DNAbilize® technology in both peer-viewed journal articles and at key oncology medical meetings. In particular, we were delighted with the interim results from our ongoing Phase 2 clinical trial of prexigebersen for the treatment of AML, which showed 47% of evaluable patients demonstrated some degree of response to prexigebersen in combination with LDAC, representing a significant advance for de-novo patients previously untreated for AML who are not otherwise eligible for standard or high-intensity chemotherapy regimens or who have elected a low intensity regimen,” said Peter Nielsen, President and CEO of Bio-Path Holdings.
- GlobeNewswire•13 days ago
Bio-Path Holdings Appoints Dr. Anas Younes to Scientific Advisory Board
Bio-Path Holdings, Inc., (BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced the appointment of Anas Younes, M.D., to its Scientific Advisory Board (SAB). “It is with great pleasure we welcome Dr. Younes, one of the world’s most renowned lymphoma experts, to our SAB. In particular, his guidance will be key as we develop our program for BP1002 in lymphoma and solid tumors,” said Peter Nielsen, President and Chief Executive Officer of Bio-Path.
- GlobeNewswire•14 days ago
Bio-Path Holdings to Announce First Quarter 2018 Financial Results on May 16, 2018
Bio-Path Holdings, Inc., (BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Wednesday, May 16, 2018 at 8:30 a.m. ET to report financial results for the first quarter ended March 31, 2018 and to provide a business overview. A live audio webcast of the call will also be available on the Presentations section of the Company’s website, www.biopathholdings.com. Bio-Path is a biotechnology company developing DNAbilize®, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous transfusion.
- GlobeNewswire•last month
Pre-Clinical Data Demonstrating Promising Potential of Prexigebersen as Treatment for Solid Tumors in Gynecologic Malignancies Presented at American Association for Cancer Research Annual Meeting
Bio-Path Holdings, Inc., (BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that data from pre-clinical studies supporting the potential of prexigebersen (BP1001, liposomal Grb2 antisense), in the treatment of solid tumors in gynecologic malignancies were presented in a poster at the annual meeting of the American Association for Cancer Research (AACR), which took place in Chicago, IL. The poster titled, “Grabbing GRB2: The use of Liposome-incorporated Grb2 antisense oligonucleotides as a novel therapy in gynecologic malignancies,” was presented by Olivia D. Lara, M.D., University of Texas MD Anderson Cancer Center, Department of Gynecologic Oncology during the Experimental and Molecular Therapeutics Poster Session. The data summarize results from studies investigating the expression of GRB2 in a series of in vitro experiments in high-grade serous (HGSC) and uterine (UC) carcinoma models. The study also examined the biological effects of prexigebersen in HGSC mice models (OVCAR 5), first in a dose-defining experiment then in combination with standard dose paclitaxel.
- ACCESSWIRE•last month
Wired News – EMA Completed Validation of MAA for Aradigm’s Linhaliq in Non-Cystic Fibrosis Bronchiectasis
Stock Monitor: Bio-Path Holdings Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 09, 2018 / Active-Investors.com has just released a free research report on Aradigm Corp. (NASDAQ: ARDM ). If you ...
- Zacks•2 months ago
Bio-Path Leukemia Combo Study Shows Positive Early Data
Bio-Path (BPTH) announces positive interim data from phase II study of its lead pipeline candidate ??? prexigebersen ??? in combination with low-dose cytarabine (LDAC) for leukemia patients.
- InvestorPlace•2 months ago
Bio-Path: Why the Biotech Penny Stock Is Skyrocketing Today
The other bit of good news for BPTH stock today was financial results for its fiscal full year of 2017. During the year, the company reported a net loss of $8.1 million, or 80 cents per share. This is a wider net loss than the $6.8 million, or 73 cents per share from the year prior.
- Benzinga•2 months ago
Benzinga Pro's 5 Stocks To Watch Today
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Long Blockchain Corp (NASDAQ: LBCC ) stock gained ...
- GlobeNewswire•2 months ago
Bio-Path Holdings Reports Full Year 2017 Financial Results
HOUSTON, April 03, 2018-- Bio-Path Holdings, Inc.,, a biotechnology company leveraging its proprietary DNAbilize ® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid ...
- GlobeNewswire•2 months ago
Bio-Path Holdings Announces Interim Data from Phase 2 Clinical Trial of Prexigebersen in Combination with Low Dose Cytarabine (LDAC) for the Treatment of Acute Myeloid Leukemia (AML)
Prexigebersen plus LDAC was well-tolerated and showed early anti-leukemic activity in nearly 50% of evaluable AML patients treated to date. Planned protocol amendments may provide for potential approvals ...
- ACCESSWIRE•2 months ago
Bio-Path Holdings, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / April 3, 2018 / Bio-Path Holdings, Inc. (NASDAQ: BPTH ) will be discussing their earnings results in their Q4 Earnings Call to be held on April 3, 2018 at 8:30 AM Eastern Time. ...
- GlobeNewswire•2 months ago
Bio-Path Holdings Announces Publication in The Lancet Haematology
HOUSTON, March 29, 2018-- Bio-Path Holdings, Inc.,, a biotechnology company leveraging its proprietary DNAbilize ® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid ...
- GlobeNewswire•2 months ago
Bio-Path Holdings to Announce Fourth Quarter and Full Year 2017 Financial Results on April 3, 2018
HOUSTON, March 27, 2018-- Bio-Path Holdings, Inc.,, a biotechnology company leveraging its proprietary DNAbilize ® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid ...
- GlobeNewswire•2 months ago
Bio-Path Holdings to Present Data at the 2018 AACR Annual Meeting
HOUSTON, March 15, 2018-- Bio-Path Holdings, Inc., a biotechnology company leveraging its proprietary DNAbilize ® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid ...
- GlobeNewswire•3 months ago
Bio-Path Holdings to Present at the 30th Annual ROTH Conference
HOUSTON, March 06, 2018-- Bio-Path Holdings, Inc.,, a biotechnology company leveraging its proprietary DNAbilize ® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid ...
- ACCESSWIRE•5 months ago
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (NASDAQ: BPTH)
DALLAS, TX / ACCESSWIRE / December 15, 2017 / Bio-Path Holdings, Inc. ("Bio-Path") (NASDAQ: BPTH): COMPANY DESCRIPTION Bio-Path Holdings, Inc. (Bio-Path) is a clinical-stage biotechnology company ...
- ACCESSWIRE•6 months ago
Corporate News Blog - Valeant Pharma Completes Sale of its Obagi Medical Products Business
Research Desk Line-up: Bio-Path Post Earnings Coverage LONDON, UK / ACCESSWIRE / November 13, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Valeant ...
- Simply Wall St.•6 months ago
Bio-Path Holdings Inc (BPTH): How Does It Impact Your Portfolio?
If you are looking to invest in Bio-Path Holdings Inc’s (NASDAQ:BPTH), or currently own the stock, then you need to understand its beta in order to understand how it canRead More...
- Associated Press•6 months ago
Bio-Path reports 3Q loss
The Bellaire, Texas-based company said it had a loss of 2 cents per share. In the final minutes of trading on Thursday, the company's shares hit 30 cents. A year ago, they were trading at $1.21. _____ ...
